Phase II Study of IMRT With SIB as Adju… | Clinical Trial

Key information

Conditions

Thyroid Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Neoplasms Neoplasms by Site Thyroid Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

About this study

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

Exclusion criteria

medullary or anaplastic thyroid cancer, unresectable

Treatment and study plan

IMRT

Procedure

Primary outcomes

toxicity according to RTOG criteria
locoregional control

Sponsors and collaborators

Lead sponsor

Alberta Health services

Other

Registry information

Official study title

Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Important dates

Study start: 2006
Primary completion: 2010
Study completion: 2010
First posted: Jan 20, 2006
Registry last updated: Jan 19, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed